Rigerimod

Peptideexperimental

Rigerimod is a polypeptide corresponding to the sequence 131-151 of the 70k snRNP protein with a serine phosphorylated in position 140. — Wikipedia

Clinical trial activity

4 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2010 (NCT01135459)

Timeline

2010s

Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Jan 1, 2010
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Lupus Erythematosus, Systemic · Phase 3

Mechanism of action

U1 small nuclear ribonucleoprotein 70 kDaINHIBITOR
SNRNP70 inhibitor
- U1 small nuclear ribonucleoprotein 70 kDa (SNRNP70) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](COP(=O)(O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O

Mol. weight: 2638.98 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

Also known as

cep-33457
forigerimod
forigerimod
forigerimod
forigerimod acetate
ipp-201101
ipp-201101
ipp-201101
ipp-201101
lupuzor
lupuzor
lupuzor
p140
p140
p140 peptide
spliceosomal peptide p140

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03427151	Phase 3	Feb 27, 2018	ImmuPharma
NCT02504645	Phase 3	Mar 1, 2015	ImmuPharma, Wallace Rheumatic Study Center
NCT01240694	Phase 3	Dec 1, 2010	Cephalon
NCT01135459	Phase 2	Jun 1, 2010	Cephalon

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Cephalon	For profit	2	2	2	2010
ImmuPharma	For profit	2	2	1	2015
Wallace Rheumatic Study Center	Academic/Hospital	1	0	1	2015

3 organizations

Page 1 / 1